Albany, NY -- (SBWIRE) -- 04/03/2019 -- Acne Vulgaris - Epidemiology and Market Forecast-2028

Twelve percent of women and five percent of men aged 25 years have acne vulgaris. By the age of 45 years, 5% of both men and women still have acne vulgaris.

- Acne Vulgaris cases are highest in the United States with approximately 47 million diagnosed prevalent cases in 2017.
- Acne Vulgaris Diagnosed Prevalent Cases is highest in the United Kingdom in 2017, whereas Spain showed the lowest number of diagnosed cases in the EU5.
- The moderate-to-severe acne affects around 20% of young people in the UK.
- Acne vulgaris is the most common skin disease in the United States as it affects an estimated 80% of Americans at some time during their lives.

DelveInsight launched a new report on Acne Vulgaris - Market Insights, Epidemiology and Market Forecast-2028

Key benefits

- Acne Vulgaris report will help to develop Business Strategies by understanding the trends shaping and driving the Acne Vulgaris market.
- Organize sales and marketing efforts by identifying the best opportunities for Acne Vulgaris market.
- To understand the future market competition in the Acne Vulgaris market.

"Acne Vulgaris is ranked as the 8th most prevalent disease worldwide and is projected to affect approximately 9.4% of the global population."

Acne Vulgaris market is segmented into topical and oral combination treatments. The therapeutic modalities have been designed based on a better understanding of the pathogenesis of acne. In topical therapy, various agents, such as benzoyl peroxide, antibiotics, topical retinoid, etc. can be used as combination medications. On the other hand, systemic therapy includes oral antibiotics, hormonal therapy, isotretinoin, and others. The advice on the therapy to be administered is based on the severity of the acne. Phototherapy and lesion removal are also found to be effective in a few cases.
The current Acne Vulgaris market is dependent on both the marketed as well as generic products. The branded marketed drugs such as Acanya (Valeant Pharmaceuticals), Tazorac (Allergan), Veltin (Almirall), Duac (GlaxoSmithKline), Epiduo and Epiduo Forte (Galderma), BenzaClin Topical Gel (Dermik Laboratories a business of Sanofi-Aventis) etc., along with antimicrobial and anti-inflammatory drugs hold the major position in the acne market. On the flip side, patent expiry of the marketed drugs is also set to impact the overall Acne Vulgaris market size.
Acne vulgaris treatments are effective, however, regimens are complex and side effects are common. A better understanding of the pathology of acne is leading to the identification of new and safer therapeutic targets. There are many products in the final phase of the pipeline, all of which are in topical therapy area and targets various mechanisms such as IDP-120 (Valeant Pharmaceuticals), ASC-J9 (AndroScience), DRM01 (DRM01), BPX-01 (BioPharmX), and AOB101 (AOBiome).

There are several companies that are working towards the development of therapeutic options like

Acne vulgaris Companies
1. Valeant Pharmaceuticals
2. Allergan
3. Almirall
4. GlaxoSmithKline
5. Galderma
and many others.

Drugs that are involved are
1. Acanya
2. Tazorac
3. Veltin
4. Duac
And many others

Table of contents

1. Report Introduction
2. Acne Vulgaris Market Overview at a Glance
3. Acne Vulgaris Disease Background and Overview
4. Epidemiology and Patient Population
5. Acne Vulgaris Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Acne Vulgaris Treatment & Medical Practices
7. Acne Vulgaris Marketed Drugs
7.1. Acanya: Valeant Pharmaceuticals
7.2. Drug Description
7.3. Tazorac: Allergan
7.4. Veltin: Almirall, S.A.
7.5. Duac: GlaxoSmithKline
7.6. Epiduo and Epiduo Forte: Galderma S.A
8. Therapeutics under Development by Companies
8.1. Key Cross Competition
8.2. Emerging Drugs
8.2.1. Sarecycline: Paratek Pharmaceuticals
8.2.2. SB204: Novan Therapeutics
9. Acne Vulgaris: Market Size
10. 7MM Acne Vulgaris: Country-Wise Market Analysis
10.1. United States
10.2. Germany
10.3. France
10.4. United Kingdom
10.5. Spain
10.6. Italy
10.7. Japan
11. Market Drivers
12. Market Barriers
13. Appendix
14. Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight